The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.
The French drug regulator, ANSM, has found fault with recommendations by the European Medicines Agency’s safety committee (PRAC) to restrict the use of medicines containing the widely used decongestant pseudoephedrine, saying that the restrictions do not go far enough.
The recommendations, announced by the EMA today, advise that pseudoephedrine-containing medicines should not be used in certain patients with high...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
